Reach Us +44-1764-910199
Eulàlia Genesca | OMICS International
ISSN: 2168-9547

Molecular Biology: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Eulàlia Genesca

Eulàlia Genesca Dra. Eulàlia Genescà ALL Research Group-IJC Carretera de Canyet s/n, Camí de les Escoles. Edifici IMPPC.08916, Badalona (Barcelona), Spain.


Eulàlia completed her doctoral thesis at the Institut de Recerca Oncològica (IRO) in Barcelona at the Department of Medical and Molecular Genetics headed by Dr. Xavier Estivill. The experimental work was focused on elucidating the functional role of unknown genes that map in the human chromosome 21 (HC21). The group named it DSCR1 (Down Syndrome Candidate Region 1) and it was reported as an endogenous regulator of calcineurin phosphatase. As a postdoctoral researcher she joined the CRG in Barcelona, where she continued working on the DSCR1 protein elucidating the inhibition mechanism. Her experience in the ALL field began when she started a postdoctoral position in France, in the laboratory of Dr. Jacques Ghysdael at the Institut Curie in Orsay, Paris. There she investigated the pro-oncogenic function of the calcineurin/NFAT pathway in a mouse model of T-ALL induced by over expression of Notch 1 in pre-leukaemic cells. The leukaemic mouse model allowed the group to find evidence that calcineurin is key for the re-initiation of leukaemia in mice. After moving to the Institut Universitaire d'Hematologie in the laboratory of Prof. Jean Soulier, also in Paris, Eulàlia's research in ALL disease became more clinically oriented. She developed a xenograft mouse model of T-ALL and used it to functionally characterize two candidate tumour suppressor genes.

Research Interest

Currently, she is in charge of the laboratory for the T-ALL research line at the Josep Carreras Leukemia Research Institute. Here her research is focused on the identification of copy number alterations as targets for available drugs involved in T-ALL leukemogenesis and prognosis.

Global Speakers in the subject

Global Experts in the subject